Shivsharan B. Dhadde

Mr. Shivsharan B. Dhadde

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SDSharanbasappa Durg
Sharanbasappa Durg
Shivsharan B. DhaddeShivsharan B. Dhadde
Shivsharan B. Dhadde
RVRavichandra Vandal
Ravichandra Vandal
BSBadamaranahalli S. Shivakumar
Badamaranahalli S. Shivakumar
CCChabbanahalli S. Charan
Chabbanahalli S. Charan

1 February 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
Shivsharan B. DhaddeShivsharan B. Dhadde
Shivsharan B. Dhadde
PNP. Nagakannan
P. Nagakannan
MRMarulasiddeshwara Roopesh
Marulasiddeshwara Roopesh
SKS.R. Anand Kumar
S.R. Anand Kumar
BTB.S. Thippeswamy
B.S. Thippeswamy
SBS. Badami
S. Badami

1 February 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SDSharanbasappa Durg
Sharanbasappa Durg
VVVeeresh P. Veerapur
Veeresh P. Veerapur
SNSatrasala Neelima
Satrasala Neelima
Shivsharan B. DhaddeShivsharan B. Dhadde
Shivsharan B. Dhadde
Embelia ribes (ER) has been documented in Ayurveda for treating various diseases, including diabetes mellitus (DM). The present systematic review and meta-analysis evaluated the efficacy and safety of ER and its active bio-marker, embelin and its derivatives in the treatment of DM. Literature search was performed in PubMed/MEDLINE, EMBASE, Scopus, ScienceDirect, Scifinder, and Google Scholar. Using Review Manager, meta-analysis of ER/embelin/derivatives of embelin versus diabetic control was performed with inverse-variance model, providing mean differences (MDs) and 95% confidence intervals (CIs). Heterogeneity was determined by I2 statistic. A total of 13 studies were included in the systematic review and meta-analysis, and were conducted in experimental rats. ER and embelin significantly (P≤0.01) resorted blood glucose (MD, -231.30; CI, -256.79, -205.82; and MD, -154.70; CI, -168.65, -140.74) and glycosylated haemoglobin (MD, -6.36; CI, -8.33, -4.39; and MD,-4.68; CI, -7.76, -1.60), respectively. Meta-analysis findings also reported considerable restoration of insulin, lipid profile, haemodynamic parameters, serum and oxidative stress markers. The derivatives of embelin, 6-bromoembelin and vilangin, also improved diabetic condition. In addition, treatments also ameliorated body weight changes due to diabetes. The present systematic review and meta-analysis supports scientific evidence for the antidiabetic activity of ER/embelin/derivatives of embelin. However, further research is warranted in clinical trials to validate the present findings.

1 May 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
SNS. Nagarjun
S. Nagarjun
Shivsharan B. DhaddeShivsharan B. Dhadde
Shivsharan B. Dhadde
VVVeeresh P. Veerapur
Veeresh P. Veerapur
BTB.S. Thippeswamy
B.S. Thippeswamy
BCBaburao N Chandakavathe
Baburao N Chandakavathe

18 February 2016 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
ASAshique Shaikh
Ashique Shaikh
Shivsharan B. DhaddeShivsharan B. Dhadde
Shivsharan B. Dhadde
SDSharanbasappa Durg
Sharanbasappa Durg
VVV. P. Veerapur
V. P. Veerapur
SBS. Badami
S. Badami
JPJagadevappa S. Patil
Jagadevappa S. Patil

1 June 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
SDSharanbasappa Durg
Sharanbasappa Durg
NBNaveen Kumar B.
Naveen Kumar B.
RVRavichandra Vandal
Ravichandra Vandal
Shivsharan B. DhaddeShivsharan B. Dhadde
Shivsharan B. Dhadde
BTB.S. Thippeswamy
B.S. Thippeswamy
SBShrishailappa Badami
Shrishailappa Badami